Clinical Trial Update: BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BST-236 as a single-agent therapy in adults with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndromes; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• BST-236

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED